Novo Nordisk Ziltivekimab ZEUS Trial: Phase 3 Cardiovascular Readout Misses Primary MACE Reduction Target
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated systemic inflammation.
Roche Biocon Perjeta Lawsuit: Genentech Sues Over Biocon’s Breast-Cancer Biosimilar in New Jersey Court
Genentech and Roche have filed a new patent-infringement lawsuit against Biocon in New Jersey federal court, alleging Biocon’s proposed pertuzumab biosimilar infringes patents covering Perjeta, Roche’s blockbuster HER2-positive breast-cancer treatment, the second major U.S. action against Biocon over the same product in 2026.
Sanofi Q2 2026 Results: Dupixent Sales Growth Powers Record Second Quarter as Guidance is Upgraded
Sanofi posted 17.8% Q2 2026 sales growth at constant exchange rates, driven by Dupixent’s record €5.2 billion quarter and a 48.3% jump in pharma launches, prompting an upgraded full-year outlook.
IQVIA Q2 2026 Results: Revenue Climbs 8.7% to $4.37 Billion, Company Raises Full-Year 2026 Guidance
IQVIA Q2 2026 results show revenue up 8.7% to $4.368 billion, Adjusted EPS of $3.15, and a raised full-year 2026 outlook, driven by record R&D Solutions bookings and accelerating Commercial Solutions growth.
GSK Q2 2026 Results: Core Operating Profit Rises 7% as Specialty Medicines and Vaccines Drive Growth
GSK’s Q2 2026 results show core operating profit up 7% to £2.8 billion, driven by Specialty Medicines and Vaccines, alongside plans for 20+ Phase III trial starts and the $10.6bn Nuvalent acquisition.
AstraZeneca H1 2026 Results: Total Revenue Climbs to $30.7 Billion as Company Reaffirms $80 Billion 2030 Ambition
AstraZeneca’s H1 2026 results show Total Revenue climbing 9% to $30,672 million and Core EPS up 12% to $5.21, powered by Oncology and Rare Disease growth, 30 new regulatory approvals, and fresh licensing deals for Zegfrovy and TQC3721 — as the company reaffirms its $80 billion 2030 revenue ambition.
Sanofi Ends Amlitelimab Atopic Dermatitis Development, Will Not Seek Global Regulatory Approval
Sanofi has discontinued amlitelimab in moderate-to-severe atopic dermatitis and will not pursue global regulatory submissions, citing ESTUARY phase 3 data that did not show a meaningful edge over standard of care. Full-year 2026 guidance is unaffected.
Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion
Samsung Biologics Q2 2026 earnings rose year-over-year to KRW 1,321 billion in revenue and KRW 586 billion in operating profit, as the CDMO advanced its Rockville facility integration, Plant 5 ramp-up, and pending PolyPeptide Group acquisition.
Danaher Corporation Q2 2026 Financial Results; Strategic Capital Allocation, and Market Valuation Dynamics
Danaher Corporation (NYSE: DHR) reported strong second-quarter 2026 financial results, generating revenue of $6.265 billion (+5.5% YoY) and non-GAAP adjusted diluted earnings per share (EPS) of $1.94 (+8.0% YoY), with both key metrics outperforming Wall Street consensus estimates. Non-GAAP core sales grew 3.0% overall and 4.5% when excluding post-pandemic respiratory testing normalizations, driven by a rebound across Life Sciences workflows and continued adoption of clinical diagnostics menus.
Novartis Q2 2026 Results: Kisqali, Kesimpta, and Pluvicto Drive Return to Sales Growth
Novartis Q2 2026 results show a return to sales growth, with net sales up 3% to $14.4 billion on strong demand for Kisqali, Kesimpta, Scemblix, and Pluvicto, as the company reaffirmed its full-year 2026 guidance and advanced key pipeline programs including Fabhalta and Rhapsido.